• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Aspire Biopharma Holdings Inc.

    5/19/25 8:30:03 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASBP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 9)


    Aspire Biopharma Holdings, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    738920107

    (CUSIP Number)


    05/06/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    738920107


    1Names of Reporting Persons

    Lance Friedman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,207,886.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,207,886.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,207,886.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.52 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Includes 2,200,886 shares of common stock held by Blackstone Capital Advisors, Inc., 7,000 shares of common stock held by Thor Special Situations LLC.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aspire Biopharma Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    194 Candelaro Drive, #233, Humacao, Puerto Rico, 00791
    Item 2. 
    (a)Name of person filing:

    Lance Friedman
    (b)Address or principal business office or, if none, residence:

    25 N Market Street, Suite 205, Jacksonville, Florida 32202
    (c)Citizenship:

    United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    738920107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (b)Percent of class:

    4.52 %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2,207,886

     (ii) Shared power to vote or to direct the vote:

    N/A

     (iii) Sole power to dispose or to direct the disposition of:

    2,207,886

     (iv) Shared power to dispose or to direct the disposition of:

    N/A

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Lance Friedman
     
    Signature:/s/ Lance Friedman
    Name/Title:Lance Friedman
    Date:05/19/2025
    Get the next $ASBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASBP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ASBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

      MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t

      4/16/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

      MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register

      4/15/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance

    $ASBP
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aspire Biopharma Holdings Inc.

      SCHEDULE 13G/A - Aspire Biopharma Holdings, Inc. (0001847345) (Subject)

      5/19/25 8:30:03 PM ET
      $ASBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aspire Biopharma Holdings Inc.

      10-Q - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

      5/14/25 4:45:22 PM ET
      $ASBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by Aspire Biopharma Holdings Inc.

      S-1 - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

      5/13/25 5:21:07 PM ET
      $ASBP
      Biotechnology: Pharmaceutical Preparations
      Health Care